Back to comparisons

Comparison

Noopept vs Selank

FieldNoopeptSelank
Categorypeptidepeptide
Dose range10–30mg0.4–0.9mg
Half-life0.5h
Onset20min
EvidenceEVIDENCEBEVIDENCEC
Safety●●●●●●●○○
Legal (US)USUnscheduledUSResearch chemical
PubMed refs9050

The comparison in plain English

Auto-generated from data

Noopept and Selank are both in the peptide category respectively. Noopept Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Selank Russian heptapeptide analog of tuftsin.

Bottom line

Noopept (evidence B, safety 4/5) has a weaker evidence base than Selank (evidence C, safety 3/5). Noopept has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.

Choose Noopept if

Noopept is the better fit when your goal aligns with its mechanism (Increases BDNF and NGF expression in the hippocampus and prefrontal cortex) and the dose range (10–30mg) suits your protocol. Half-life is 0.5h.

Choose Selank if

Selank is the better fit when your goal aligns with its mechanism (Heptapeptide structurally analogous to tuftsin, an endogenous tetrapeptide with immunomodulating activity) and the dose range (0.4–0.9mg) suits your protocol. Half-life is —h.

Build a stack with bothOpen builder →
Check interactionsOpen checker →